Rifaximin is as effective as the low-FODMAP diet in managing irritable bowel syndrome and offers quicker symptom relief and ...

"Former blockbuster Linzess grows label with paediatric IBS-C approval" was originally created and published by ...

The US medicines regulator has approved Linzess (linaclotide) capsules for children aged seven years and older with irritable ...

The FDA expands use of linaclotide to children as young as age 7 years with irritable bowel syndrome with constipation (IBS-C ...

The FDA has updated the label indication for linaclotide capsules for the treatment of irritable bowel syndrome with ...

Rimegepant is already FDA-approved for acute treatment of migraine and preventive treatment of episodic migraine in adults.

FDA approves IBS drug for children, Linzess, to treat pediatric IBS-C in patients ages 7 and older with proven safety and efficacy.

Therapies to alter behaviour could be the most effective first step to cure irritable bowel syndrome, more than existing go-to treatments, a new study suggests. Irritable bowel syndrome, or IBS, is a ...

The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of irritable bowel syndrome with constipation (IBS-C) in patients 7 years of age and older. Previously, ...

B. Longum is known as a “good bacteria” that helps break down food and absorb nutrients, which can help ease digestive ...

Initially approved in 2012, linaclotide is already indicated for treating chronic idiopathic constipation and IBS-C in adults ...

The company now expects revenue of $270 and $275 million for its Ibsrela treatment for the full year, up from $250 million to $260 million previously. The updated outlook comes as Ibsrela continues to ...